Trial record 1 of 1 for:    "Maternal hyperphenylalaninemia"
Previous Study | Return to List | Next Study

Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

This study has been completed.
Sponsor:
Information provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00065299
First received: July 21, 2003
Last updated: June 23, 2005
Last verified: May 2000
  Purpose

Phenylketonuria (PKU) is a rare genetic condition. If not treated, PKU can cause severe mental retardation. Women with PKU are advised to eat a special diet when pregnant to prevent mental retardation in their children. This study will evaluate the effects of that diet on the children of mothers with PKU.


Condition Intervention
Phenylketonuria
Behavioral: Restricted phenylalanine diet

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome

Resource links provided by NLM:


Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Estimated Enrollment: 572
Study Start Date: May 1984
Estimated Study Completion Date: April 2000
Detailed Description:

PKU is an autosomal recessive trait caused by the absence of phenylalanine hydroxylase. Phenylalanine hydroxylase is an enzyme involved in the metabolism of phenylalanine (Phe). When phenylalanine hydroxylase is absent or defective, Phe levels rise and toxic Phe metabolites accumulate, causing central nervous system injury. PKU is a treatable disease. Affected individuals must adhere to a diet low in Phe during childhood. Women with PKU should also adhere to a low Phe diet before and during pregnancy to avoid fetal damage. The offspring of women with untreated maternal hyperphenylalaninemia (HPA) usually exhibit mental retardation, microcephaly, growth retardation, and other congenital anomalies. This study will examine the effect of a restricted Phe diet on reproductive outcome in women with maternal HPA.

Participants in this study will be women with HPA whose blood Phe values are persistently greater than 4 mg/dl. Those women with blood Phe values consistently greater than 8 mg/dl will be placed on a Phe restricted diet to maintain plasma Phe concentrations between 2 and 8 mg/dl. This level of control is practical and achievable. Due to a gradient of increasing Phe level from mother to fetus, levels in the latter would vary from 3.5 to 12 mg/dl; these levels are usually associated with normal outcomes. Women will be monitored throughout their pregnancy on obstetric, biochemical, and nutritional parameters. Women on the Phe restricted diet will be given enough Phe-limited protein, calories, vitamins, and minerals to maintain adequate nutritional status. Folate supplementation will be provided. If indicated clinically, tyrosine (Tyr) and supplemental trace metals will be prescribed.

A matching control sample of women and their offspring will be developed in collaboration with associated coordinating and collaborating centers. The offspring of both groups of mothers will be followed as long as the project permits. Those offspring born to mothers admitted to the project during the first 2 to 3 years of the study will be assessed on their intellectual ability and physical health, as well as academic achievement in school. Those admitted during the last 3 to 4 years of the study will be assessed on their intellectual ability and physical health, recognizing that limited data will be available for these offspring.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  • Live in community setting
  • Become pregnant or give birth during the term of the investigation
  • Identified early in pregnancy
  • Dietary therapy instituted prior to conception whenever possible
  • Diagnosis of PKU based on results of Phe challenge, or clear diagnostic evidence in medical record
  • Blood Phe > 4 mg/dl
  • Intellectually able to understand and comply with the requirements of the Phe restricted diet, understand an informed consent, and adequately communicate with clinic personnel
  • IQ > 70

Inclusion Criteria for Controls

  • Heterozygous sisters to HPA women
  • Matched control from maternity facility; pregnancy and offspring from a non-PKU female and a PKU male

Exclusion Criteria

  • Women with evidence of pterin defect
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065299

Locations
United States, California
University of Southern California School of Medicine
Los Angeles, California, United States, 90027
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States
United States, Texas
University of Texas Medical Branch at Galveston
Galveston, Texas, United States
Sponsors and Collaborators
Investigators
Principal Investigator: Richard Koch, M.D. University of Southern California
Principal Investigator: Reuben Matalon, M.D. University of Illinois at Chicago
Principal Investigator: Bobbye M. Rouse, M.D. University of Texas at Galveston
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00065299     History of Changes
Other Study ID Numbers: NICHD-PKU, 1N01HD23148, 1N01HD23155, 1N01HD23156
Study First Received: July 21, 2003
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
Hyperphenylalaninemia
PKU
Maternal PKU
Pregnancy outcome
Phenylalanine restricted diet
Tyrosine supplementation
Maternal hyperphenylalanemia during pregnancy

Additional relevant MeSH terms:
Phenylketonurias
Phenylketonuria, Maternal
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Pregnancy Complications

ClinicalTrials.gov processed this record on August 28, 2014